Combination treatment with sublethal ionizing radiation and the proteasome inhibitor, bortezomib, enhances death-receptor mediated apoptosis and anti-tumor immune attack

International Journal of Molecular Sciences

Volumn 16, Issue 12, 2015, Pages 30405-30421

  Cacan, Ercan ^a   Spring, Alexander M ^b   Kumari, Anita ^b   Greer, Susanna F ^c   Garnett Benson, Charlie ^b  

^a GAZIOSMANPASA UNIVERSITY   (Turkey)

^b GEORGIA STATE UNIVERSITY   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

Author keywords

Anti tumor immunity; Death receptors; Proteasome; Radiation

Indexed keywords

BORTEZOMIB; DEATH RECEPTOR; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ANTIGEN; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; ANTINEOPLASTIC AGENT; PROTEASOME INHIBITOR;

ANTITUMOR IMMUNITY; APOPTOSIS; APOPTOSIS ASSAY; ARTICLE; BIOASSAY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CELL VIABILITY; COLORECTAL TUMOR; COMET ASSAY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE KILLING ASSAY; DEATH RECEPTOR ASSAY; DNA REPAIR; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNITY; IONIZING RADIATION; MRNA EXPRESSION ASSAY; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; CELL LINE; DRUG EFFECTS; EPITHELIUM CELL; HCT 116 CELL LINE; METABOLISM; RADIATION RESPONSE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BORTEZOMIB; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; EPITHELIAL CELLS; HCT116 CELLS; HUMANS; PROTEASOME INHIBITORS; RADIATION, IONIZING; RECEPTORS, DEATH DOMAIN;

EID: 84951325962     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms161226238     Document Type: Article

References (59)

1. Siegel, R.; Desantis, C.; Jemal, A. Colorectal cancer statistics, 2014. J. Cancer Res. Clin. 2014, 64, 104-117. [CrossRef] [PubMed]
2. Takeda, T.; Akita, H.; Takeda, T.; Nakamura, K.; Kobayashi, S.; Takeda, H. Immunotherapy and hyperthermia for the treatment of patients with advanced or recurrent colorectal cancer. Gan to kagaku ryoho. Cancer Chemother. 2013, 40, 1606-1608.
3. Ahmed, M.M.; Guha, C.; Hodge, J.W.; Jaffee, E. Immunobiology of radiotherapy: New paradigms. Radiat. Res. 2014, 182, 123-125. [CrossRef] [PubMed]
4. Casati, A.; Varghaei-Nahvi, A.; Feldman, S.A.; Assenmacher, M.; Rosenberg, S.A.; Dudley, M.E.; Scheffold, A. Clinical-scale selection and viral transduction of human naive and central memory CD8+ T cells for adoptive cell therapy of cancer patients. Cancer Immunol. Immunother. 2013, 62, 1563-1573. [CrossRef] [PubMed]
5. Cheng, M.; Chen, Y.; Xiao, W.; Sun, R.; Tian, Z. NK cell-based immunotherapy for malignant diseases. Cell. Mol. Immunol. 2013, 10, 230-252. [CrossRef] [PubMed]
6. Grimm, M.; Kim, M.; Rosenwald, A.; von Raden, B.H.; Tsaur, I.; Meier, E.; Heemann, U.; Germer, C.T.; Gasser, M.; Waaga-Gasser, A.M. Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer. Eur. J. Cancer 2010, 46, 2314-2323. [CrossRef] [PubMed]
7. Pryczynicz, A.; Guzinska-Ustymowicz, K.; Kemona, A. Fas/FasL expression in colorectal cancer. An immunohistochemical study. Folia Histochem. Cytobiol. 2010, 48, 425-429. [CrossRef] [PubMed]
8. Zhu, Q.; Liu, J.Y.; Xu, H.W.; Yang, C.M.; Zhang, A.Z.; Cui, Y.; Wang, H.B. Mechanism of counterattack of colorectal cancer cell by Fas/Fas ligand system. World J. Gastroenterol. 2005, 11, 6125-6129. [CrossRef] [PubMed]
9. Petak, I.; Danam, R.P.; Tillman, D.M.; Vernes, R.; Howell, S.R.; Berczi, L.; Kopper, L.; Brent, T.P.; Houghton, J.A. Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma. Cell Death Differ. 2003, 10, 211-217. [CrossRef] [PubMed]
10. Koornstra, J.J.; Kleibeuker, J.H.; van Geelen, C.M.; Rijcken, F.E.; Hollema, H.; de Vries, E.G.; de Jong, S. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J. Pathol. 2003, 200, 327-335. [CrossRef] [PubMed]
11. Mirandola, P.; Ponti, C.; Gobbi, G.; Sponzilli, I.; Vaccarezza, M.; Cocco, L.; Zauli, G.; Secchiero, P.; Manzoli, F.A.; Vitale, M. Activated human NK and CD8+ T cells express both TNF-related apoptosis-inducing ligand (TRAIL) and TRAIL receptors but are resistant to TRAIL-mediated cytotoxicity. Blood 2004, 104, 2418-2424. [CrossRef] [PubMed]
12. Allen, J.E.; El-Deiry, W.S. Regulation of the human TRAIL gene. Cancer Biol. Ther. 2012, 13, 1143-1151. [CrossRef] [PubMed]
13. Kykalos, S.; Mathaiou, S.; Karayiannakis, A.J.; Patsouras, D.; Lambropoulou, M.; Simopoulos, C. Tissue expression of the proteins fas and fas ligand in colorectal cancer and liver metastases. J. Gastrointest. Cancer 2012, 43, 224-228. [CrossRef] [PubMed]
14. Perraud, A.; Akil, H.; Nouaille, M.; Petit, D.; Labrousse, F.; Jauberteau, M.O.; Mathonnet, M. Expression of p53 and DR5 in normal and malignant tissues of colorectal cancer: Correlation with advanced stages. Oncol. Rep. 2011, 26, 1091-1097. [CrossRef] [PubMed]
15. Ifeadi, V.; Garnett-Benson, C. Sub-lethal irradiation of human colorectal tumor cells imparts enhanced and sustained susceptibility to multiple death receptor signaling pathways. PLoS ONE 2012, 7, e31762.
16. Kumari, A.; Cacan, E.; Greer, S.F.; Garnett-Benson, C. Turning T cells on: Epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J. Immunother. Cancer 2013, 1, 1-17. [CrossRef] [PubMed]
17. Garnett, C.T.; Palena, C.; Chakraborty, M.; Tsang, K.Y.; Schlom, J.; Hodge, J.W. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004, 64, 7985-7994. [CrossRef] [PubMed]
18. Agassi, A.M.; Myslicki, F.A.; Shulman, J.M.; Rotterman, Y.; Dosoretz, D.E.; Fernandez, E.; Mantz, C.A.; Finkelstein, S.E. The promise of combining radiation therapy and immunotherapy: Morbidity and toxicity. Future Oncol. 2014, 10, 2319-2328. [CrossRef] [PubMed]
19. Bedford, L.; Paine, S.; Sheppard, P.W.; Mayer, R.J.; Roelofs, J. Assembly, structure, and function of the 26S proteasome. Trends Cell Biol. 2010, 20, 391-401. [CrossRef] [PubMed]
20. Chen, D.; Dou, Q.P. The ubiquitin-proteasome system as a prospective molecular target for cancer treatment and prevention. Curr. Protein Pept. Sci. 2010, 11, 459-470. [CrossRef] [PubMed]
21. Kinyamu, H.K.; Jefferson,W.N.; Archer, T.K. Intersection of nuclear receptors and the proteasome on the epigenetic landscape. Environ. Mol. Mutagen. 2008, 49, 83-95. [CrossRef] [PubMed]
22. Bhat, K.P.; Greer, S.F. Proteolytic and non-proteolytic roles of ubiquitin and the ubiquitin proteasome system in transcriptional regulation. Biochim. Biophys. Acta 2011, 1809, 150-155. [CrossRef] [PubMed]
23. Bross, P.F.; Kane, R.; Farrell, A.T.; Abraham, S.; Benson, K.; Brower, M.E.; Bradley, S.; Gobburu, J.V.; Goheer, A.; Lee, S.L.; et al. Approval summary for bortezomib for injection in the treatment of multiple myeloma. Clin. Cancer Res. 2004, 10, 3954-3964. [CrossRef] [PubMed]
24. Niewerth, D.; Dingjan, I.; Cloos, J.; Jansen, G.; Kaspers, G. Proteasome inhibitors in acute leukemia. Expert Rev. Anticancer Ther. 2013, 13, 327-337. [CrossRef] [PubMed]
25. Schumacher, L.Y.; Vo, D.D.; Garban, H.J.; Comin-Anduix, B.; Owens, S.K.; Dissette, V.B.; Glaspy, J.A.; McBride, W.H.; Bonavida, B.; Economou, J.S.; et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J. Immunol. 2006, 176, 4757-4765. [CrossRef] [PubMed]
26. Shanker, A.; Brooks, A.D.; Tristan, C.A.; Wine, J.W.; Elliott, P.J.; Yagita, H.; Takeda, K.; Smyth, M.J.; Murphy, W.J.; Sayers, T.J. Treating metastatic solid tumors with bortezomib and a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist antibody. J. Natl. Cancer Inst. 2008, 100, 649-662. [CrossRef] [PubMed]
27. Seki, N.; Toh, U.; Sayers, T.J.; Fujii, T.; Miyagi, M.; Akagi, Y.; Kusukawa, J.; Kage, M.; Shirouzu, K.; Yamana, H. Bortezomib sensitizes human esophageal squamous cell carcinoma cells to TRAIL-mediated apoptosis via activation of both extrinsic and intrinsic apoptosis pathways. Mol. Cancer Ther. 2010, 9, 1842-1851. [CrossRef] [PubMed]
28. Zhao, Y.; Foster, N.R.; Meyers, J.P.; Thomas, S.P.; Northfelt, D.W.; Rowland, K.M., Jr.; Mattar, B.I.; Johnson, D.B.; Molina, J.R.; Mandrekar, S.J.; et al. A Phase I/II Study of Bortezomib in Combination with Paclitaxel, Carboplatin and Concurrent Thoracic Radiation Therapy for Non-Small Cell Lung Cancer: NCCTG-N0321. J. Thorac. Oncol. 2014, 10, 172-180. [CrossRef] [PubMed]
29. Huang, Z.; Peng, S.; Knoff, J.; Lee, S.; Yang, B.; Wu, T.C.; Hung, C.F. Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8+ T cell immune response and antitumor effects in a preclinical cervical cancer model. J. Biomed. Sci. 2015, 22, 899-908. [CrossRef] [PubMed]
30. Ostling, O.; Johanson, K.J. Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells. Biochem. Biophys. Res. Commun. 1984, 123, 291-298. [CrossRef]
31. Calini, V.; Urani, C.; Camatini, M. Comet assay evaluation of DNA single-and double-strand breaks induction and repair in C3H10T1/2 cells. Cell Biol. Toxicol. 2002, 18, 369-379. [CrossRef] [PubMed]
32. Huerta, S.; Heinzerling, J.H.; Anguiano-Hernandez, Y.M.; Huerta-Yepez, S.; Lin, J.; Chen, D.; Bonavida, B.; Livingston, E.H. Modification of gene products involved in resistance to apoptosis in metastatic colon cancer cells: Roles of Fas, Apaf-1, NFkappaB, IAPs, Smac/DIABLO, and AIF. J. Surg. Res. 2007, 142, 184-194. [CrossRef] [PubMed]
33. Yang, F.; Jove, V.; Chang, S.; Hedvat, M.; Liu, L.; Buettner, R.; Tian, Y.; Scuto, A.; Wen, W.; Yip, M.L.; et al. Bortezomib induces apoptosis and growth suppression in human medulloblastoma cells, associated with inhibition of AKT and NF-kB signaling, and synergizes with an ERK inhibitor. Cancer Biol. Ther. 2012, 13, 349-357. [CrossRef] [PubMed]
34. Jane, E.P.; Premkumar, D.R.; Pollack, I.F. Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-kB signaling pathway. Mol. Cancer Ther. 2011, 10, 198-208. [CrossRef] [PubMed]
35. Sunwoo, J.B.; Chen, Z.; Dong, G.; Yeh, N.; Crowl Bancroft, C.; Sausville, E.; Adams, J.; Elliott, P.; van Waes, C. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin. Cancer Res. 2001, 7, 1419-1428. [PubMed]
36. Wright, J.J. Combination therapy of bortezomib with novel targeted agents: An emerging treatment strategy. Clin. Cancer Res. 2010, 16, 4094-4104. [CrossRef] [PubMed]
37. Uziel, O.; Cohen, O.; Beery, E.; Nordenberg, J.; Lahav, M. The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma. Transl. Oncol. 2014, 7, 741-751. [CrossRef] [PubMed]
38. Chang, H.Y.; Huang, T.C.; Chen, N.N.; Huang, H.C.; Juan, H.F. Combination therapy targeting ectopic ATP synthase and 26S proteasome induces ER stress in breast cancer cells. Cell Death Dis. 2014, 5, e1540. [CrossRef] [PubMed]
39. Kunami, N.; Katsuya, H.; Nogami, R.; Ishitsuka, K.; Tamura, K. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma. Anticancer Res. 2014, 34, 5287-5294. [PubMed]
40. Pervan, M.; Iwamoto, K.S.; McBride, W.H. Proteasome structures affected by ionizing radiation. Mol. Cancer Res. 2005, 3, 381-390. [CrossRef] [PubMed]
41. Dunn, G.P.; Old, L.J.; Schreiber, R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21, 137-148. [CrossRef] [PubMed]
42. Rosenberg, S.A.; Restifo, N.P.; Yang, J.C.; Morgan, R.A.; Dudley, M.E. Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat. Rev. Cancer 2008, 8, 299-308. [CrossRef] [PubMed]
43. Blattman, J.; Greenberg, P. Cancer immunotherapy: A treatment for the masses. Science 2004, 305, 200-205. [CrossRef] [PubMed]
44. Zhang, J.Y.; Casiano, C.A.; Peng, X.X.; Koziol, J.A.; Chan, E.K.; Tan, E.M. Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol. Biomark. Prev. 2003, 12, 136-143.
45. Tsang, K.Y.; Zaremba, S.; Nieroda, C.A.; Zhu, M.Z.; Hamilton, J.M.; Schlom, J. Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. J. Natl. Cancer Inst. 1995, 87, 982-990. [CrossRef] [PubMed]
46. Gulley, J.L.; Arlen, P.M.; Tsang, K.Y.; Yokokawa, J.; Palena, C.; Poole, D.J.; Remondo, C.; Cereda, V.; Jones, J.L.; Pazdur, M.P.; et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin. Cancer Res. 2008, 14, 3060-3069. [CrossRef] [PubMed]
47. Lesterhuis,W.J.; de Vries, I.J.; Schreibelt, G.; Schuurhuis, D.H.; Aarntzen, E.H.; de Boer, A.; Scharenborg, N.M.; van De Rakt, M.; Hesselink, E.J.; Figdor, C.G.; et al. Immunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients. Anticancer Res. 2010, 30, 5091-5097. [PubMed]
48. Mohebtash, M.; Tsang, K.Y.; Madan, R.A.; Huen, N.Y.; Poole, D.J.; Jochems, C.; Jones, J.; Ferrara, T.; Heery, C.R.; Arlen, P.M.; et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 2011, 17, 7164-7173. [CrossRef] [PubMed]
49. Tawa, P.; Tam, J.; Cassady, R.; Nicholson, D.W.; Xanthoudakis, S. Quantitative analysis of fluorescent caspase substrate cleavage in intact cells and identification of novel inhibitors of apoptosis. Cell Death Differ. 2001, 8, 30-37. [CrossRef] [PubMed]
50. Schneider, P.; Thome, M.; Burns, K.; Bodmer, J.L.; Hofmann, K.; Kataoka, T.; Holler, N.; Tschopp, J. TRAIL receptors 1 (DR4) and 2 (DR5) signal FADD-dependent apoptosis and activate NF-kB. Immunity 1997, 7, 831-836. [CrossRef]
51. Nawrocki, S.T.; Carew, J.S.; Pino, M.S.; Highshaw, R.A.; Andtbacka, R.H.; Dunner, K., Jr.; Pal, A.; Bornmann, W.G.; Chiao, P.J.; Huang, P.; et al. Aggresome disruption: A novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 2006, 66, 3773-3781. [CrossRef] [PubMed]
52. Kaeser, M.D.; Pebernard, S.; Iggo, R.D. Regulation of p53 stability and function in HCT116 colon cancer cells. J. Biol. Chem. 2004, 279, 7598-7605. [CrossRef] [PubMed]
53. Rodrigues, N.R.; Rowan, A.; Smith, M.E.; Kerr, I.B.; Bodmer, W.F.; Gannon, J.V.; Lane, D.P. p53 mutations in colorectal cancer, Proc. Natl. Acad. Sci. USA 1990, 87, 7555-7559. [CrossRef]
54. Mariadason, J.M.; Arango, D.; Shi, Q.; Wilson, A.J.; Corner, G.A.; Nicholas, C.; Aranes, M.J.; Lesser, M.; Schwartz, E.L.; Augenlicht, L.H. Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003, 63, 8791-8812. [PubMed]
55. Finkelstein, S.E.; Fishman, M. Clinical opportunities in combining immunotherapy with radiation therapy. Front. Oncol. 2012, 2, 169. [CrossRef] [PubMed]
56. Weber, D.C.; Ares, C.; Lomax, A.J.; Kurtz, J.M. Radiation therapy planning with photons and protons for early and advanced breast cancer: An overview. Radiat. Oncol. 2006, 1, 1-22. [CrossRef] [PubMed]
57. Chen, D.; Frezza, M.; Schmitt, S.; Kanwar, J.; Dou, Q.P. Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr. Cancer Drug Targets 2011, 11, 239-253. [CrossRef] [PubMed]
58. Gyori, B.M.; Venkatachalam, G.; Thiagarajan, P.S.; Hsu, D.; Clement, M.V. OpenComet: An automated tool for comet assay image analysis. Redox Biol. 2014, 2, 457-465. [CrossRef] [PubMed]
59. Cacan, E.; Ali, M.W.; Boyd, N.H.; Hooks, S.B.; Greer, S.F. Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance. PLoS ONE 2014, 9, e87455.